Abstract: Cancer of the vulva accounts for at least 1% of malignant neoplasms among women. Although rare, vulvar melanoma is the second most common histological type of vulvar cancer, representing 7-10% of all malignant vulvar neoplasms. Initial symptoms are non-specific and complete excision of the lesion is indicated in cases with suspected diagnosis. Prognosis of patients with these neoplasms is poor and remains unchanged despite the treatment approach. Hemivulvectomy with lymph node dissection is the current procedure of choice, associated or not with adjuvant therapies. We report two cases of patients presenting with late diagnosed vulvar melanoma and the relevant aspects in their therapeutic management.
INTRODUCTION
Cancer of the vulva is a rare neoplasm, accounting for less than 1% of malignant neoplasms among women. It represents 3-5%
of malignant neoplasms of the female genital tract and has an estimated incidence of 1-2 cases per 100,000 women/year. 1 The most frequent histological type is epidermoid carcinoma, responsible for over 90% of cases of cancer of this organ, followed by melanoma (5-6%). Sarcoma, basal cell carcinoma, and vulvar Paget's disease account for less than 2% of cases. 1, 2 With regard to location, the labia majora is the most commonly affected site (52%) followed by the labia minora (18%), clitoris (10-15%) and Bartholin´s glands (1-3%). 2, 3 Although rare, vulvar melanoma is the second most common histological type of vulvar cancer, representing 7-10% of all malignant vulval neoplasms. 5 However, gynecologists and dermatologists may relatively often encounter this neoplasm, particularly within referral centers. Given that lesion size is a determinant for prognosis, early detection of the tumor is of vital importance. 4, 5 Two cases of advanced vulvar melanoma in patients treated at the pelvic oncology center of a college hospital are reported below. 
CASES REPORT

DISCUSSION
Vulvar melanoma is a rare disease whose histological types, in order of incidence, are mucosal lentiginous (27-57%), nodular (22-28%), unclassified (12-16%), and superficial spreading (4-56%).
5
Complete excision of the lesion is indicated in cases with suspected diagnosis. Currently, surgery still remains the best option albeit without the need for radical procedures. A number of studies have shown that radical surgery does not increase patient's survival with initial disease compared to local excision with margins, and is associated with greater morbidity and anatomical disfiguring.
Consequently, radical vulvectomy with bilateral lymphadenectomy is becoming a questionable and obsolete treatment approach.
Alternatively, wide local excision with a 1cm surgical margin is rec- ommended for lesions with a depth of less than 1mm and en bloc resection for deeper lesions, with a safety margin of 2-3 cm and regional lymphadenectomy (inguinal-femoral). 6 Adjuvant treatment with immunotherapy, chemotherapy, and radiotherapy may be recommended in specific cases and for local recurrences and distal metastases. 7 The main prognostic factors include tumor site, depth of invasion, presence of ulceration, and occurrence of lymph node metastases. In addition, patient's age and tumor stage also appear to be critical factors in the survival of women with vulvar melanoma. 8 Irrespective of stage, the literature shows that 5-year survival rates are around 20-56%. 9 The behavior of primary malignant vulvar and extragenital cutaneous melanomas appear to be similar. However, some studies have shown that the general prognosis of patients with vulvar melanoma is worse than that of women with extragenital melanoma and squamous cell carcinoma of the vulva, showing a greater tendency for local and distal recurrence. 7, 10 Although rare, vulvar melanoma can be relatively often encountered in Oncology referral centers. The condition must be diagnosed as early as possible in order to improve the prognosis and survival of patients. q
